The present invention reports the synthesis and characterization of innovative PEGylated liposomes targeting therapeutic anti-apoptotic protein KillerTRAIL and the use of resulting therapeutic and targeted nanocarirers for anti-cancer and anti-inflammatory therapies. The synthesis of KillerTRAIL PEGylated liposomes were carried out by the conjugation of therapeutic proteins on the surface of nanocarriers and the anti-cancer activity in vitro was carried out in breast cancer cells which are used as cancer model for the experimetns.
Liposomal system with Killer TNF-apoptosis induced ligand (KillerTRAIL), pro-apoptotic-directing.
Celia C;Cilurzo F;
2021-01-01
Abstract
The present invention reports the synthesis and characterization of innovative PEGylated liposomes targeting therapeutic anti-apoptotic protein KillerTRAIL and the use of resulting therapeutic and targeted nanocarirers for anti-cancer and anti-inflammatory therapies. The synthesis of KillerTRAIL PEGylated liposomes were carried out by the conjugation of therapeutic proteins on the surface of nanocarriers and the anti-cancer activity in vitro was carried out in breast cancer cells which are used as cancer model for the experimetns.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
WO2021245547A1.pdf
Solo gestori archivio
Tipologia:
PDF editoriale
Dimensione
5.24 MB
Formato
Adobe PDF
|
5.24 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
